Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 14/20 | 0.67 |
| ▸ | CRBN | Q96SW2 | 14/20 | 0.67 |
| ▸ | FPR3 | P25089 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30706039 | 1.00 | DDB1 (0.67) | DDB1CRBNFPR3FPR2KDM1A | |
| SCHEMBL30706148 | 0.87 | DDB1 (0.70) | DDB1CRBNKDM1A | |
| SCHEMBL30705914 | 0.87 | DDB1 (0.70) | DDB1CRBNKDM1A | |
| SCHEMBL30794089 | 0.85 | DDB1 (0.74) | DDB1CRBN | |
| SCHEMBL30793998 | 0.85 | DDB1 (0.74) | DDB1CRBN | |
| SCHEMBL30705896 | 0.83 | DDB1 (0.50) | DDB1CRBNFPR3FPR2KDM1A | |
| SCHEMBL30029207 | 0.83 | DDB1 (0.81) | DDB1CRBN | |
| SCHEMBL30706175 | 0.82 | DDB1 (0.63) | DDB1CRBN | |
| SCHEMBL30705954 | 0.81 | DDB1 (0.51) | DDB1CRBNFPR3FPR2KDM1A | |
| SCHEMBL30661576 | 0.80 | DDB1 (0.72) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270191-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-08-28 | — | — | US | disclosed |
| EP-4536649-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023244918-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270191-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | DDB1 141/4885CRBN 756/4885FPR3 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.